4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019)

4D Molecular Therapeutics' (FDMT) quarterly Preferred Stock Liabilities came in at $103.0 million in Q4 2019.

4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019) Analysis & Trends

4D Molecular Therapeutics (FDMT) has 1 years of Preferred Stock Liabilities data on file, last reported at $103.0 million in Q4 2019.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $103.0 million in Q4 2019; TTM through Dec 2019 was $103.0 million, a N/A change from a year earlier, with the FY2019 full-year figure at $103.0 million, changed N/A from the prior year.
Preferred Stock Liabilities for Q4 2019 stood at $103.0 million.
Over the last five years, Preferred Stock Liabilities for FDMT reached as high as $103.0 million in Q4 2019 and fell as low as $103.0 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	4D Molecular Therapeutics	706.51 Mn	315.62 Mn	-	-

Download Data

Date	Value
Dec 31, 2019	102.98 Mn